• Elizabeth Topp

    Irish Research Center Hires Purdue Prof

    Ireland’s National Institute for Bioprocessing Research and Training has hired Purdue's Elizabeth Topp as chief science officer. She has served as professor in the college of pharmacy and is an acknowledged global leader in drug product manufacturing. Topp's research has focused on the chemical and physical stability of protein drugs, which she has patented through the Purdue Research Foundation Office of Technology Commercialization.
  • Decio Eizirik

    IBRI Announces Diabetes Research Team

    The Indiana Biosciences Research Institute has named Decio Eizirik (pictured) research fellow for its diabetes research center. Also, Donalyn Scheuner was recently named senior staff scientist. Eizirik most recently served as professor and director of the Université Libre de Bruxelles center for diabetes research in Brussels. Scheuner previously served as scientific consultant and senior scientist with Eli Lilly and Company.

  • Mike Harrington and Patrik Jonsson

    Lilly Announces Changes in Senior Leadership

    Eli Lilly and Company has announced several changes to the company's executive committee. Mike Harrington (pictured), senior vice president and general counsel, will retire at the end of the year. Christi Shaw, senior vice president and president Lilly Bio-Medicines, has announced she will leave at the end of August. Patrik Jonsson (pictured), currently president and general manager of Lilly Japan, will succeed Shaw.  

  • Patty Martin

    BioCrossroads Appoints Lilly Exec CEO

    After a national search, BioCrossroads has announced Patty Martin will become the life science initiative's next president and chief executive officer. Martin, who most recently served as chief operating officer for Lilly Diabetes, will begin her new role Monday.  

  • IBRI Chief Steps Down, Takes New Role

    The Indiana Biosciences Research Institute has announced Chief Executive Officer and Chief Scientific and Innovation Officer Rainer Fischer has stepped down from both roles. The institute says Fischer, who came to Indianapolis in 2017, will remain as a senior executive for innovation and discovery. In his new role, Fischer will work to attract new partners for sponsored and contract research, as well as new donors.

  • Eric Miller

    16 Tech Adds Director of Business Development

    The 16 Tech Community Corp. has named Eric Miller director of business development. He previously worked in commercial real estate in the Research Triangle Region of North Carolina for more than 15 years, most recently serving as vice president of Brokerage with Real Estate Associates Inc., a leading commercial real estate firm in Durham.

  • Shane Springer

    Springer Joins Conexus Indiana

    Conexus Indiana has named Shane Springer director of industry engagement, where he will lead a statewide networked community of advanced manufacturers representing a broad range of industry sectors. He most recently served as director of government and legislative affairs for the Indiana Department of Workforce Development.

  • David Johnson

    BioCrossroads CEO Moving On

    The chief executive officer of the state's life sciences initiative is stepping down. BioCrossroads says David Johnson, who has led the organization for 14 years, is leaving at the end of the year to focus full-time on his role as president and CEO of the Central Indiana Corporate Partnership. He was elected president and CEO of the CICP in 2012 and has since led both organizations in a shared capacity.

  • AquaBounty Names New CEO

    A Massachusetts-based company, with a presence in east central Indiana, has named a new chief executive officer. AquaBounty Technologies Inc. says Sylvia Wulf, who currently serves as senior vice president of US Foods Inc., will begin her new role in January. Wulf will succeed Ronald Stotish, who will remain with the company as an executive director with responsibility for research and regulatory affairs. 

  • William "Bill" Nowatzke

    B2S Life Sciences Names VP

    Franklin-based B2S Life Sciences LLC, a biotherapeutic drug development company, has appointed William "Bill" Nowatzke vice president of laboratory operations and clinical laboratory improvement amendments testing. He is a board-certified clinical chemist with more than 20 years of academic, industry and contract research organization experience.

  • Todd Young

    Elanco Names Young CFO

    Elanco Animal Health Inc. has named Todd Young as executive vice president and chief financial officer. He has more than 20 years of experience in a wide range of financial roles. Most recently, Young served as executive vice president and CFO for ACADIA Pharmaceuticals Inc. in San Diego.

  • Anne White

    White Promoted to President of Lilly Oncology

    Eli Lilly and Co. has promoted Anne White to senior vice president of Lilly and president of Lilly Oncology. She will become a member of Lilly's executive committee, reporting directly to Chairman and Chief Executive Officer David Ricks. White succeeds Sue Mahony who retired. White most recently served as vice president of portfolio management, chorus and next generation research & development.

  • Cara Frosch

    Pearl Pathways Hires Business Development Director

    Pearl Pathways has hired Cara Frosch as director of business development. She has more than 35 years of diversified biopharmaceutical and medical device experience in human and animal health. Most recently, Frosch spent 12 years at Eli Lilly and Co. / Elanco, where she led new product planning, global portfolio and market intelligence initiatives.

  • Michael-Bryant Hicks

    Elanco Names Hicks General Counsel

    Elanco Animal Health has named Michael-Bryant Hicks general counsel. He joins the division of Eli Lilly and Co. at its Greenfield headquarters. Hicks has almost 20 years of corporate legal experience. Most recently, he served as general counsel at Mallinckrodt Pharmaceuticals, where he performed legal functions on behalf of the company.

  • Robyn Durr-Henry and Mark Cameron

    AIT Bioscience Adds to Leadership Team

    AIT Bioscience LLC has promoted Robyn Durr-Henry (pictured) to senior director of quality assurance. The life sciences firm has also named Mark Cameron (pictured) vice president of scientific services and ligand binding assays, Jeff Goddard vice president of business development and Ray Fitzpatrick director of commercial operations.

  • Nancy Kant

    Pearl Pathways Hires Clinical Services Advisor

    Pearl Pathways has hired Nancy Kant as clinical services advisor to support biopharmaceutical and diagnostic life science companies. Kant’s career includes 16 years at Eli Lilly and Co., 12 years at Roche Diagnostics Corp. (formerly Boehringer Mannheim Corp.), and eight years in academia. Most recently, she served as a technical process expert at Eli Lilly and was responsible for the operational and quality management of PET tracer development programs.

  • Sue Mahony

    Lilly Oncology President to Retire

    The president of Lilly Oncology has announced plans to retire. Indianapolis-based Eli Lilly and Co. says Sue Mahony will step down from the role at the end of August after 18 years with the company. Mahony also serves as senior vice president of Lilly and a member of Lilly's executive committee. She joined the company in 2000 and has held senior leadership roles in product development, marketing and general management.

  • James Bourdage

    Bourdage to Retire as BASi VP of Bioanalytical Operations

    West Lafayette-based Bioanalytical Systems Inc. has announced James Bourdage (pictured) is retiring. He is vice president of bioanalytical operations. Michael Baim will succeed Bourdage effective May 7. Before joining the company nearly four years ago, Bourdage spent his career in the pharmaceutical industry. He served in leadership positions at Covance, PharmAthene, Eli Lilly and Co. and Pharmacia/Upjohn.

  • Leena Gandhi

    Gandhi to Lead Lilly Oncology Immuno-Oncology Medical Development

    Eli Lilly and Co. has announced Leena Gandhi will join Lilly Oncology June 25 to lead immuno-oncology medical development. She is currently director of thoracic medical oncology and an associate professor of medicine at the New York University School of Medicine. Gandhi will lead a team of scientists that oversees the Lilly Oncology immunotherapy portfolio.

  • Christopher Jensen

    Elanco Names CFO

    Greenfield-based Elanco Animal Health has named Christopher Jensen senior vice president and chief financial officer. He most recently served as CFO of Celanese Corp. Jensen's previous experience includes financial planning and analysis, treasury, tax, accounting, financial shared services, audit and IT. 

  • Tedd Green (photo courtesy Cook Group)

    Former Cook Pharmica President Lands New Role

    The New Jersey-based company that acquired Cook Pharmica in Bloomington is making some organizational changes. Catalent Inc. has selected former Cook Pharmica President Tedd Green to serve as senior vice president of Catalent Biologics. Green will be responsible for the company’s entire biologics business and will operate out of Catalent’s Bloomington facility.

  • IBRI Grows Executive Team

    Mark Craft has joined the Indiana Biosciences Research Institute as executive director of engagement, communications and external affairs. Prior to joining IBRI, he served as assistant vice president for marketing and media at Purdue University, beginning in 2014. Craft has also held executive positions in corporate communications at Raytheon, Anthem, Duke Energy, Hillenbrand and Simon Property Group.

  • Ketan Paranjape

    Roche Appoints VP of Diagnostics Information Solutions

    Roche Diagnostics has appointed Ketan Paranjape vice president of diagnostics information solutions. He will oversee the company’s new DIS commercial business. In his new role, Paranjape will establish commercialization strategies to market Roche’s digital software solutions. He previously served as managing director of business development for Health2047.

  • Jeff Carnahan

    EnviroForensics Names Jeff Carnahan President

    Indianapolis-based EnviroForensics has announced Jeff Carnahan (pictured) will succeed Nancy Shields as president. He will lead the company’s commitment to restoring environmentally impacted properties for the benefit of private and public customers. Carnahan previously served as executive vice president.

  • Endocyte¬†Inc. Adds to Team

    West Lafayette-based Endocyte Inc. has named Caryn Barnett senior director, clinical operations with global responsibility for Endocyte clinical trials. She most recently served as director of clinical operations, North America oncology at Eli Lilly and Co. Also, Theresa Bruce has been appointed head of European clinical operations following 25 years in the field of clinical research, with the last 20 dedicated to oncology.

  • Heidi Unger

    Pearl Pathways Adds Unger as Analyst

    Indianapolis-based Pearl Pathways has named Heidi Unger regulatory publication analyst to support biopharmaceutical, medical device and diagnostic life science companies. She previously spent 15 years at John Wiley and Sons. Unger earned a BA in English and Journalism from Franklin College.

  • Allison Giles

    Cook Group Promotes Giles

    Bloomington-based Cook Group has promoted Allison Giles to vice president of federal and international government affairs. Since 2009, she has served as vice president of federal affairs. Giles will continue leading Cook’s efforts in Washington, D.C. and will now also lead the global international government affairs program for Cook Group, and its affiliates.

  • Robert Seevers

    Former FDA Regulatory Scientist Joins Pearl Pathways

    Pearl Pathways has hired Robert Seevers as senior advisor to serve biopharmaceutical companies. He has more than 40 years of experience in pharmaceutical research and development for both large and small molecules. His expertise includes CMC regulatory, cold chain shipping, setting global specifications, quality by design (QbD), global regulatory submissions, and interactions with global regulatory agencies.

  • Sarena Lin

    Elanco Adds Senior VP

    Elanco Animal Health has named Sarena Lin senior vice president of North America Operations and Global Strategy. She will manage the company's U.S. and Canadian food and companion animal businesses. Lin most recently oversaw Cargill's global animal feed and nutrition business.

  • Jay McGill

    IBRI Taps Lilly Vet For COO Spot

    The Indiana Biosciences Research Institute in Indianapolis has selected Jay McGill as chief operating officer. He comes to the position after working for Indianapolis-based Eli Lilly and Co. for 28 years, most recently serving as senior director of Lilly Research Laboratories Operations.

  • Dr. Kimberly Blackwell (photo courtesy Duke University)

    Lilly Oncology Names VP

    Eli Lilly and Co. has named Kimberly Blackwell vice president of early phase development and immuno-oncology. She will join Lilly Oncology March 12. Blackwell is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center. She also serves as co-director of the Duke women's cancer program, associate director for strategic relations for the Duke Cancer Institute and research scholar for Susan G. Komen.

  • Lilly Promotes Johnson to Senior VP

    Eli Lilly and Co. has promoted Philip Johnson to senior vice president, finance and treasurer. He currently serves as vice president for investor relations. Johnson has been with Lilly 22 years, serving in a variety of financial roles in the U.S. and overseas.

  • Angie's List Exec to Lead Conexus

    Indiana's advanced manufacturing and logistics initiative Conexus Indiana has appointed a new chief executive officer. Mark Howell succeeds Steve Dwyer, who is retiring at the end of the year. Howell most recently served as chief operating officer at Angie's List. He has been involved with Conexus since 2007, serving on the organization's board.

  • Lilly Announces Senior Leadership Appointments

    Eli Lilly and Co. has promoted: Josh Smiley, senior VP and CFO; Dan Skovronsky, senior VP for science and technology and president of Lilly Research Labs and Myles O'Neill, senior VP and president of manufacturing operations. Aarti Shah has been named an executive officer. Also, Maria Crowe (pictured), president of manufacturing operations and Jan Lundberg (pictured), president of Lilly Research Labs, are retiring.

  • David Broecker to Step Aside as IBRI CEO

    The Indiana Biosciences Research Institute in Indianapolis has named its next chief executive officer. Rainer Fischer, who will continue to serve as chief scientific and innovation officer, will succeed David Broecker (pictured) as CEO October 1. Broecker, the IBRI's founding CEO, will stay on as an advisor to the institute. Fischer came to the IBRI last year from the Fraunhofer Institute for Molecular Biology and Applied Ecology in Germany.

  • Pearl Pathways Hires Senior Advisor

    Pearl Pathways has hired Mark Slisz as a senior advisor serving biopharmaceutical, medical device and diagnostic life science companies. He previously directed the CMC regulatory strategy and risk assessment for Endocyte Inc. and he also held roles in regulatory, manufacturing, process development and research at Eli Lilly and Co. 

  • IBRI Hires Research Fellow and Digital Tech VP

    A former Eli Lilly and Co. executive has been named research fellow and vice president of digital technology at the Indiana Biosciences Research Institute in Indianapolis. Daniel Robertson previously served as senior director of research IT at Lilly and spent the last two years building out the IBRI's computational analytics, digital and data sciences capabilities. He also launched the institute's Applied Data Sciences Core.

  • Zimmer Biomet CEO Steps Down

    Warsaw-based Zimmer Biomet Holdings Inc. President and Chief Executive Officer David Dvorak has stepped down. The company says he also stepped down from the board of directors, but will remain in an advisory capacity for an undisclosed period of time. Senior Vice President and Chief Financial Officer Daniel Florin will serve as interim CEO, in addition to his current duties.  

  • Pearl Pathways Hires Clinical Research Associate

    Pearl Pathways has added Masheka Fuqua as a clinical research associate serving biopharmaceutical, medical device and diagnostic life science companies. She brings more than a decade of clinical research experience to the company, including the coordination, management, and submissions of clinical trial activity across many therapeutic areas of research.

  • Lilly Names Pusey Senior VP

    Eli Lilly and Co. has named Leigh Ann Pusey senior vice president of corporate affairs and communications. She currently serves as president and CEO of the American Insurance Association, an insurance industry trade association representing more than 300 insurers that provide property and casualty insurance in the United States. Pusey joined AIA in 1996 and was promoted to president and CEO in February 2009.

  • Crosswind Pharmacy Names Director

    Crosswind Pharmacy has named Dirk Harris director of pharmacy services. He joined the Northwind Pharmaceuticals team in November 2016 to help complete the development of Crosswind. With more than 28 years of pharmacy leadership experience, Harris brings extensive clinical and management expertise to Crosswind.

  • Pearl Pathways Adds to Team

    Indianapolis-based Pearl Pathways has named Shawn Knopp an advisor serving medical device and biopharmaceutical life science companies. He brings more than 15 years of experience in multi-disciplinary life science roles including project management, product development, regulatory, engineering and manufacturing.The company has also named Waylon Wright as a marketing and sales associate.

  • Pearl Pathways Hires Quality Analyst

    Pearl Pathways has named Phillip Bishop as a quality analyst serving medical device and biopharmaceutical life science companies. He brings 13 years of quality control laboratory experience to the company and recently held leadership roles in a good manufacturing practice compliant QC laboratory at a top-tier contract manufacturer of sterile products.

  • Pearl Pathways Hires Analyst

    Indianapolis-based Pearl Pathways has named Michele Taylor a regulatory compliance analyst serving medical device and biopharmaceutical life science companies. She previously worked for Beckman Coulter, where she managed project work on custom integrated lab automation systems for the drug discovery and research industries. 

  • IBRI Names Research Fellow

    The Indiana Biosciences Research Institute has named Michael Pugia a research fellow and director of the new Bioanalytics Core Laboratory. He comes to the IBRI following a 30-year career in the biomedical in-vitro diagnostic industry.

  • Apexian Pharmaceuticals Appoints CEO

    Apexian Pharmaceuticals Inc., previously known as ApeX Therapeutics, has appointed Steve Carchedi president and chief executive officer. He succeeds David Broecker, who is now CEO of the Indiana Biosciences Research Institute. Carchedi will also become a member of the company's board of directors.

  • Biotech Company Adds to Leadership Team

    Indianapolis-based Assembly Biosciences Inc. has added several senior-level leaders, including chief scientific officer. The company says the new hires will focus on advancing its expanding microbiome platform. Miguel Barbosa will now serve as CSO of the Microbiome Program.

  • Lilly Oncology Names VP

    Indianapolis-based Eli Lilly & Co. has named Levi Garraway senior vice president of global development and medical affairs for Lilly Oncology. He will begin his new role January 1, following the retirement of Richard Gaynor. Garraway currently serves as professor of medicine at Harvard Medical School in Massachusetts.

  • Lilly Makes Changes to Leadership Team

    Indianapolis-based Eli Lilly and Co. has appointed Joshua Smiley senior vice president of finance and treasurer, starting October 1. He succeeds Thomas Grein, who is retiring in September after 41 years with the company. Smiley currently serves as senior vice president of finance and controller and chief financial officer of Lilly Research Laboratories.

  • TriMedx Names Schneider COO

    Indianapolis-based TriMedx has named Richard Schneider chief operating officer. Prior to joining TriMedx, he served in several executive roles with Asurion. In this role, Schneider will focus on overall operations in addition to customer and employee relationships. 

  • Senior Leadership Appointments Announced for DowDuPont

    DuPont and The Dow Chemical Co. have announced several senior leadership appointments for DowDuPont. The appointments include: Howard Ungerleider, CFO; Stacy Fox, general counsel; Charles Kalil, special counsellor to the executive chairman, general counsel for DowDuPont's Material Science business; Jim Fitterling, COO for the Material Science business and James Collins, COO for DowDuPont's Agriculture business.

  • IBRI Names Execs

    The Indiana Biosciences Research Institute has named a chief financial officer and a director of external affairs and communications. Mark Anderson (pictured) will serve as CFO and vice president of administration. Christy Denault has been named director of external affairs and communications.

  • Indiana Blood Center Names New CEO

    The Indiana Blood Center has named Charles Miraglia chief executive officer. He most recently served as chief medical officer of Indianapolis-based hc1.com and has held a variety of leadership roles in the health care sector over the last 20 years.
  • Indiana Blood Center Names New Directors

    The Indiana Blood Center has hired Damon Clements as director of information technology and promoted Penny Schroeder to department director of blood collections. Clements previously served as IT director at Regenstrief Institute, and Schroeder was manager of blood collections. 
  • Endocyte Names Chief Medical Officer

    West Lafayette-based Endocyte Inc. has named Alison Armour chief medical officer. She previously served as vice president of oncology at Novartis and GSK.